Wolff Wiese Magana LLC Lantern Pharma Inc. Transaction History

Wolff Wiese Magana LLC

$141 Million
Q3 2024

A detailed history of Wolff Wiese Magana LLC transactions in Lantern Pharma Inc. stock. As of the latest transaction made, Wolff Wiese Magana LLC holds 600 shares of LTRN stock, worth $2,136. This represents 0.0% of its overall portfolio holdings.

Number of Shares

600

Previous 600 -0.0%

Holding current value

$2,136

Previous $2,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 16, 2024	SELL	$2.48 - $4.39 $3,968 - $7,023	-1,600 Reduced 72.73%	600 $2,000
Q3 2023 Oct 30, 2023	SELL	$3.41 - $5.51 $78,242 - $126,426	-22,945 Reduced 91.25%	2,200 $7,000
Q2 2023 Aug 01, 2023	SELL	$4.56 - $6.02 $6,078 - $8,024	-1,333 Reduced 5.03%	25,145 $141,000
Q1 2023 Apr 18, 2023	SELL	$4.3 - $6.2 $2,666 - $3,844	-620 Reduced 2.29%	26,478 $127,000
Q4 2022 Feb 08, 2023	SELL	$4.19 - $6.04 $14,095 - $20,318	-3,364 Reduced 11.04%	27,098 $163,000
Q3 2022 Oct 26, 2022	SELL	$4.59 - $6.5 $5,108 - $7,234	-1,113 Reduced 3.52%	30,462 $146,000
Q2 2022 Jul 15, 2022	SELL	$4.82 - $7.45 $22,075 - $34,121	-4,580 Reduced 12.67%	31,575 $180,000
Q1 2022 May 09, 2022	BUY	$5.6 - $8.22 $11,312 - $16,604	2,020 Added 5.92%	36,155 $259,000
Q4 2021 Jan 18, 2022	SELL	$7.11 - $11.04 $8,396 - $13,038	-1,181 Reduced 3.34%	34,135 $272,000
Q3 2021 Oct 15, 2021	BUY	$10.53 - $14.93 $73,678 - $104,465	6,997 Added 24.71%	35,316 $395,000
Q2 2021 Jul 15, 2021	BUY	$12.94 - $19.89 $16,097 - $24,743	1,244 Added 4.59%	28,319 $413,000
Q1 2021 Apr 15, 2021	BUY	$14.34 - $21.92 $388,255 - $593,484	27,075 New	27,075 $491,000

Others Institutions Holding LTRN

# of Institutions

Shares Held

1.31M

Call Options Held

39.8K

Put Options Held

6.1K

View Full List

About Lantern Pharma Inc.

Ticker LTRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 10,830,900
Market Cap $38.6M
Description
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-30...

More about LTRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolff Wiese Magana LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolff Wiese Magana LLC with notifications on news.

Account

Wolff Wiese Magana LLC Lantern Pharma Inc. Transaction History